Altimmune (ALT) announced a CEO succession plan under which Vipin Garg, Ph.D. will step down as the Company’s President and CEO effective January 1, 2026. Altimmune’s Chairman of the Board, Jerry Durso, will assume the role of President and CEO and retain his position as Chairman. To facilitate a smooth transition, Dr. Garg will serve as an advisor to the Company through June 30, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune announces publication of IMPACT Phase 2b trial data
- Altimmune announce results from analysis of biopsies from IMPACT Phase 2b trial
- Altimmune price target lowered to $14 from $15 at Citizens JMP
- Altimmune Reports Q3 2025 Financial and Business Progress
- Altimmune’s Earnings Call: Financial Growth and Clinical Progress